Document Detail

Isoprodian and rifampicin in the treatment of leprosy: a descriptive evaluation of therapy durations in 475 Paraguayan leprosy patients.
MedLine Citation:
PMID:  2676405     Owner:  NLM     Status:  MEDLINE    
In Paraguay, the National Leprosy/Tuberculosis Program is based on a combined chemotherapy with isoprodian and rifampicin. The aim of this descriptive study was to investigate the therapy durations used so far in the treatment of 475 leprosy patients and to analyze the criteria responsible for the wide-ranging differences in therapy durations. As initial criteria, the following parameters were identified to have a significant influence on the therapy duration: Patients never treated before or pretreated, clinical classification and initial bacteriological index (BI) value. During therapy, conditions like the attendance and BI decrease/year showed a significant correlation with the therapy duration. Even though the studied criteria did not allow to draw a definite conclusion with regard to an 'ideal' therapy duration, they proved to be reliable, as only 2 patients have relapsed so far.
S Pritze; A E Alvarenga; O Leguizamon; I Haubitz
Related Documents :
22738395 - Extended pelvic lymph node dissection does not affect erectile function recovery in pat...
22310405 - Mid-term outcome of opening-wedge high tibial osteotomy for varus arthritic knees.
22323685 - A prospective study comparing the functional outcome of computer-assisted and conventio...
22552615 - Comparison of femoral tunnel length between transportal and retrograde reaming outside-...
18463945 - Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthr...
19932845 - The role of rapid pacu parathyroid hormone in reducing post-thyroidectomy hypocalcemia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chemotherapy     Volume:  35     ISSN:  0009-3157     ISO Abbreviation:  Chemotherapy     Publication Date:  1989  
Date Detail:
Created Date:  1989-11-21     Completed Date:  1989-11-21     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  373-82     Citation Subset:  IM    
Armauer-Hansen-Institut, Würzburg, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dapsone / therapeutic use*
Drug Combinations / therapeutic use
Drug Therapy, Combination
Isoniazid / therapeutic use*
Isonicotinic Acids / therapeutic use*
Leprostatic Agents / therapeutic use*
Leprosy / drug therapy*
Leprosy, Borderline / drug therapy
Leprosy, Lepromatous / drug therapy
Leprosy, Tuberculoid / drug therapy
Mycobacterium leprae / drug effects,  isolation & purification
Patient Compliance
Prothionamide / therapeutic use*
Rifampin / therapeutic use*
Time Factors
Reg. No./Substance:
0/Drug Combinations; 0/Isonicotinic Acids; 0/Leprostatic Agents; 13292-46-1/Rifampin; 14222-60-7/Prothionamide; 54-85-3/Isoniazid; 55015-10-6/isoprodian; 80-08-0/Dapsone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Potencies of ceftriaxone and cefotaxime in a single chamber pharmacokinetic system simulating their ...
Next Document:  Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parente...